Sooma Medical revealed on Friday that it has passed the US patent for its new stimulation electrode for safe and effective delivery of all neuromodulation therapies.
The company added that its electrode technology reduces the resistance in the skin-electrode interface when compared to competing solutions as well as faster patient preparation and superior accuracy in delivery of the stimulation dose. The hydrophilic properties of the material ensure stable contact for extended periods of time.
This neuromodulation technology is the result of a long term research project with industrial and academic partners finally reaching product stage. Since the launch, more than 1000 patients worldwide have received Sooma tDCS treatment in more than 20.000 treatment sessions.
Under its IP portfolio, the company now strengthens its position as the leading provider of home-based neuromodulation solutions with a unique product portfolio. Sooma tDCS is a therapy product using weak electrical stimulation and is intended for the treatment of major depressive disorder (MDD), chronic pain and fibromyalgia.
In addition, the company has obtained regulatory approvals for the product in the EU (Class IIa), Canada, Mexico, Singapore, Australia, Malaysia, Indonesia, and Turkey. In the US, the US FDA limits the use of the tDCS for investigational use only. Its products are distributed in over 30 countries.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial